UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 11 2025
0mins
Should l Buy DHR?
Source: TipRanks
UnitedHealth Group Stock Performance: UnitedHealth Group's stock has plummeted over 50% year-to-date due to weak Q1 earnings and a lowered full-year outlook, prompting investors to consider ETFs like Harbor Health Care ETF (MEDI) and T. Rowe Price Health Care ETF (TMED) for diversified exposure.
ETF Details and Ratings: The MEDI ETF has a Strong Buy consensus with a 42.79% upside potential, while the TMED ETF holds a Moderate Buy rating with a 41.31% upside potential; both provide indirect exposure to UNH stock, reducing investment risk.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 190.100
Low
240.00
Averages
266.18
High
310.00
Current: 190.100
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Danaher Corporation Schedules Q1 2026 Earnings Call
- Earnings Call Scheduled: Danaher Corporation will hold its Q1 2026 earnings conference call on April 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which financial performance and future expectations will be discussed.
- Webcast Details: The call will be webcast on Danaher's website under the 'Investors' section, with accompanying slides available, ensuring real-time information access for investors.
- Replay Availability: A replay of the conference call will be available until May 5, 2026, allowing investors to access the information by dialing the specified numbers, enhancing information accessibility.
- Company Overview: Danaher is a leading global innovator in life sciences and diagnostics, committed to improving human health through science and technology, with approximately 60,000 associates focused on scientific excellence and innovation.
See More
Danaher Corporation Schedules Q1 2026 Earnings Call
- Earnings Call Scheduled: Danaher Corporation will hold its Q1 2026 earnings conference call on April 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which the company will discuss its financial performance and future expectations.
- Webcast Details: The call and accompanying slide presentation will be webcast on the 'Investors' section of Danaher's website, ensuring that investors can access key information in real-time.
- Replay Availability: A replay of the conference call will be available until May 5, 2026, allowing investors who cannot attend live to review the discussion.
- Financial Materials Release: Danaher will post its earnings press release and related materials at 6:00 a.m. on the day of the call, ensuring investors have access to the latest financial data and analysis before the meeting.
See More
Halper Sadeh LLC Investigates Danaher Corporation Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers of Danaher Corporation breached their fiduciary duties, potentially leading to financial losses for shareholders and impacting corporate governance.
- Legal Fee Arrangement: The firm offers legal services on a contingent fee basis, ensuring shareholders do not incur upfront costs while pursuing their rights, thereby encouraging broader participation.
- Importance of Shareholder Involvement: Active shareholder participation can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately boosts shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, showcasing their expertise in protecting investor rights.
See More
Analysis of Increased Stake in Cardinal Health
- Increased Stake: We purchased 90 shares of Cardinal Health at approximately $217, raising our total holdings to 350 shares and increasing its weight from 1.46% to about 2%, demonstrating confidence in the company's future growth potential.
- Market Performance Analysis: Despite the healthcare sector's poor performance this week, Cardinal Health's stock drop is not tied to fundamentals, providing more upside to our $260 price target, reflecting a misunderstanding of the stock by the market.
- Industry Dynamics: The drug distribution sector is under pressure, particularly McKesson, which saw a 5% drop in shares following the announcement of its longtime CFO's retirement, indicating market sensitivity to leadership changes, even though this transition was planned.
- Investment Strategy: We are leveraging our ample cash position to increase our stake in Cardinal Health, replacing our exit from Danaher, which has fallen about 3% since last week, showcasing our ability to flexibly adjust our portfolio amid market fluctuations.
See More
Market Recap: Oil Prices Surge, CrowdStrike Upgraded
- Market Volatility: The S&P 500 fell on Monday but briefly rebounded after the U.S. and Israel launched an attack on Iran, causing oil prices to spike; WTI crude prices, while off their highs, indicate a defensive market stance.
- CrowdStrike Upgrade: Piper Sandler upgraded CrowdStrike from hold to buy with a $520 price target, arguing that the nearly 19% year-to-date pullback is excessive, and sees AI as an opportunity rather than a threat, boosting market confidence.
- Nvidia Strategic Investments: Nvidia shares rose over 3% after being named a top pick by Morgan Stanley, with analysts noting that despite stagnant stock performance in the last two quarters, business has strengthened; the company announced $2 billion investments in both Coherent and Lumentum, highlighting its strategic focus in optics technology.
- Investor Recommendations: Jim Cramer advised investors without Nvidia positions to buy the stock, asserting that its current depressed price won't last long, even as Monday's gains still left shares lower year-to-date.
See More
Novo Nordisk Invests €432 Million to Expand Wegovy Production
- Investment Expansion: Novo Nordisk announced a €432 million ($506 million) investment in Ireland to expand production capacity for the Wegovy pill, aiming to meet future global demand, particularly outside the U.S. market.
- Competitive Pressure: This investment follows Novo losing market share to Eli Lilly, with analysts noting that despite competitive pressures, this move demonstrates the company's commitment to the oral medication market, potentially helping to restore market confidence.
- Supply Assurance: Novo has stated that it has resolved supply issues for Wegovy and has enough product to meet U.S. demand; however, challenges remain in meeting global demand, especially as it seeks to launch in other countries.
- Future Outlook: The construction projects in Ireland are set to be completed gradually between 2027 and 2028, expected to include technological upgrades of existing facilities, further enhancing Novo's competitiveness in the obesity drug market, particularly in its strategic focus on oral medications.
See More
Danaher Corporation Schedules Q1 2026 Earnings Call
- Earnings Call Scheduled: Danaher Corporation will hold its Q1 2026 earnings conference call on April 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which financial performance and future expectations will be discussed.
- Webcast Details: The call will be webcast on Danaher's website under the 'Investors' section, with accompanying slides available, ensuring real-time information access for investors.
- Replay Availability: A replay of the conference call will be available until May 5, 2026, allowing investors to access the information by dialing the specified numbers, enhancing information accessibility.
- Company Overview: Danaher is a leading global innovator in life sciences and diagnostics, committed to improving human health through science and technology, with approximately 60,000 associates focused on scientific excellence and innovation.
See More
Danaher Corporation Schedules Q1 2026 Earnings Call
- Earnings Call Scheduled: Danaher Corporation will hold its Q1 2026 earnings conference call on April 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which the company will discuss its financial performance and future expectations.
- Webcast Details: The call and accompanying slide presentation will be webcast on the 'Investors' section of Danaher's website, ensuring that investors can access key information in real-time.
- Replay Availability: A replay of the conference call will be available until May 5, 2026, allowing investors who cannot attend live to review the discussion.
- Financial Materials Release: Danaher will post its earnings press release and related materials at 6:00 a.m. on the day of the call, ensuring investors have access to the latest financial data and analysis before the meeting.
See More
Halper Sadeh LLC Investigates Danaher Corporation Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers of Danaher Corporation breached their fiduciary duties, potentially leading to financial losses for shareholders and impacting corporate governance.
- Legal Fee Arrangement: The firm offers legal services on a contingent fee basis, ensuring shareholders do not incur upfront costs while pursuing their rights, thereby encouraging broader participation.
- Importance of Shareholder Involvement: Active shareholder participation can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately boosts shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, showcasing their expertise in protecting investor rights.
See More
Analysis of Increased Stake in Cardinal Health
- Increased Stake: We purchased 90 shares of Cardinal Health at approximately $217, raising our total holdings to 350 shares and increasing its weight from 1.46% to about 2%, demonstrating confidence in the company's future growth potential.
- Market Performance Analysis: Despite the healthcare sector's poor performance this week, Cardinal Health's stock drop is not tied to fundamentals, providing more upside to our $260 price target, reflecting a misunderstanding of the stock by the market.
- Industry Dynamics: The drug distribution sector is under pressure, particularly McKesson, which saw a 5% drop in shares following the announcement of its longtime CFO's retirement, indicating market sensitivity to leadership changes, even though this transition was planned.
- Investment Strategy: We are leveraging our ample cash position to increase our stake in Cardinal Health, replacing our exit from Danaher, which has fallen about 3% since last week, showcasing our ability to flexibly adjust our portfolio amid market fluctuations.
See More
Market Recap: Oil Prices Surge, CrowdStrike Upgraded
- Market Volatility: The S&P 500 fell on Monday but briefly rebounded after the U.S. and Israel launched an attack on Iran, causing oil prices to spike; WTI crude prices, while off their highs, indicate a defensive market stance.
- CrowdStrike Upgrade: Piper Sandler upgraded CrowdStrike from hold to buy with a $520 price target, arguing that the nearly 19% year-to-date pullback is excessive, and sees AI as an opportunity rather than a threat, boosting market confidence.
- Nvidia Strategic Investments: Nvidia shares rose over 3% after being named a top pick by Morgan Stanley, with analysts noting that despite stagnant stock performance in the last two quarters, business has strengthened; the company announced $2 billion investments in both Coherent and Lumentum, highlighting its strategic focus in optics technology.
- Investor Recommendations: Jim Cramer advised investors without Nvidia positions to buy the stock, asserting that its current depressed price won't last long, even as Monday's gains still left shares lower year-to-date.
See More
Novo Nordisk Invests €432 Million to Expand Wegovy Production
- Investment Expansion: Novo Nordisk announced a €432 million ($506 million) investment in Ireland to expand production capacity for the Wegovy pill, aiming to meet future global demand, particularly outside the U.S. market.
- Competitive Pressure: This investment follows Novo losing market share to Eli Lilly, with analysts noting that despite competitive pressures, this move demonstrates the company's commitment to the oral medication market, potentially helping to restore market confidence.
- Supply Assurance: Novo has stated that it has resolved supply issues for Wegovy and has enough product to meet U.S. demand; however, challenges remain in meeting global demand, especially as it seeks to launch in other countries.
- Future Outlook: The construction projects in Ireland are set to be completed gradually between 2027 and 2028, expected to include technological upgrades of existing facilities, further enhancing Novo's competitiveness in the obesity drug market, particularly in its strategic focus on oral medications.
See More
